Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Université Paris Descartes

Fondation Imagine

Assistance Publique-hopitaux De Paris

Assistance Publique - Hopitaux De Paris (aphp)

Universite Paris Cité

Université De Bourgogne

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Université Grenoble Alpes

Université Paris Diderot-paris 7

Université Paris—sud

Ab Science

American University of Beirut

Université De Caen Normandie

Olivier Hermine

Jean-Benoit Arlet

Flavia Guillem

Hugues De The

Ali Bazarbachi

Carmen Garrido-Fleury

Renaud Seigneuric

Zakia Belaid-Choucair

Emmanuel Heron

Genevieve Courtois

Alain Moussy

Jean-Pierre Kinet

Michaela Fontenay

Claude Cochet

Michel Paques

Odile Filhol-Cochet

Matthieu Montes

Yves Colin

Jean-Luc Wautier

Yves Colin Aronovicz

Gandhi Damaj

Marie-Paule Wautier

Jean-Antoine Ribeil

Sophia Ladraa

Thiago Trovati Maciel

Slimane Allali

Caroline Carvalho

Rachel Rignault-bricard

Genevève Courtois

Jean-Francois Girmens

Marie Thérèse Rubio

Leila Maouche-Chretien

Marie Bouillie

Maria Leite De Maraes

Ivan Cruz-Moura

Etienne Paubelle

Michael Dussiot

Christine Bodemer

Laura Polivka

Guillaume Marcion

Florence Zylbersztejn

Jean-François Girmens

Geneviève Courtois

Jean-Benoît Arlet

Maria Leite De Moraes

A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sickle cell disease in a patient in need thereof. Also, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and/or treatment of acute chest syndrome (ACS) in a sickle cell disease patient in need thereof.

Masitinib for the treatment of sickle cell disease

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway

The inventors demonstrate for the first time the activation of the Hedgehog (HH) signaling pathway in normal and abnormal human mast cells (MCs). These results prompt the inventors to explore the consequence of the inhibition of the HH pathway, especially the canonical pathway, on MC proliferation. They demonstrate that Hedgehog inhibitors inhibit proliferation and induces apoptosis of mast cells. Accordingly the present invention relates to a method of treating a mast cell disease in a patient in need there of comprising administering to the patient a therapeutically effective amount of a Hedgehog inhibitor.

Methods and pharmaceutical compositions for the treatment of mast cell diseases

The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA &#x394; 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.

Methods and pharmaceutical compositions for the treatment of systemic mastocytosis

The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.

Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1

The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.

Use of hydroxycarbamide for preventing retinal nonperfusion

The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(&#x2212;) iNKT cell sub-population. In particular, CD3+CD4&#x2212; TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.

Methods for determining the risk of acute graft versus host disease

The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.

Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse

The present invention relates to methods and pharmaceutical compositions for the treatment of beta-thalassemias. In particular, the present invention relates to an XPO1 inhibitor for use in a method for treating beta-thalassemia in a subject in need thereof.

Methods and pharmaceutical compositions for the treatment of beta-thalassemias

The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.

Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes

The present invention relates to methods and compositions for the treatment of retinal vein occlusion.

Methods and pharmaceutical compositions for treatment of retinal occlusion

Methods and compositions for the treatment of &#x3b2;-thalassemia are provided. Methods and compositions restore or increase erythrocyte maturation in individuals afflicted with &#x3b2;-TM by preventing proteolysis of GATA-1 protein. Screening methods for identifying agents which bind heat shock protein 70 (HSP-70) and inhibit HSP-70 &#x3b1;-globin binding, but which allow GATA-1 protein-HSP-1 binding in a manner that prevents GATA-1 proteolysis.

Methods and compositions for the treatment of &#x3b2;-thalassemia

The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.

Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma

Growing community of inventors

Paris, France

Olivier Hermine